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ABSTRACT
OBJECTIVE
To compare the efficacy, safety, and cost utility of 
continuous subcutaneous insulin infusion (CSII) with 
multiple daily injection (MDI) regimens during the first 
year following diagnosis of type 1 diabetes in children 
and young people.
DESIGN
Pragmatic, multicentre, open label, parallel group, 
randomised controlled trial and economic evaluation.
SETTING
15 paediatric National Health Service (NHS) diabetes 
services in England and Wales. The study opened to 
recruitment in May 2011 and closed in January 2017.
PARTICIPANTS
Patients aged between 7 months and 15 years, with 
a new diagnosis of type 1 diabetes were eligible 
to participate. Patients who had a sibling with the 
disease, and those who took drug treatments or 
had additional diagnoses that could have affected 
glycaemic control were ineligible.
INTERVENTIONS
Participants were randomised, stratified by age and 
treating centre, to start treatment with CSII or MDI 
within 14 days of diagnosis. Starting doses of aspart 
(CSII and MDI) and glargine or detemir (MDI) were 
calculated according to weight and age, and titrated 
according to blood glucose measurements and 
according to local clinical practice.
MAIN OUTCOME MEASURES
Primary outcome was glycaemic control (as measured 
by glycated haemoglobin; HbA1c) at 12 months. 
Secondary outcomes were percentage of patients in 
each treatment arm with HbA1c within the national 
target range, incidence of severe hypoglycaemia and 
diabetic ketoacidosis, change in height and body 
mass index (as measured by standard deviation 
scores), insulin requirements (units/kg/day), partial 
remission rate (insulin dose adjusted HbA1c <9), 
paediatric quality of life inventory score, and cost 
utility based on the incremental cost per quality 
adjusted life year (QALY) gained from an NHS costing 
perspective.
RESULTS
294 participants were randomised and 293 included 
in intention to treat analyses (CSI, n=144; MDI, 
n=149). At 12 months, mean HbA1c was comparable 
with clinically unimportant differences between CSII 
and MDI participants (60.9 mmol/mol v 58.5 mmol/
mol, mean difference 2.4 mmol/mol (95% confidence 
interval −0.4 to 5.3), P=0.09). Achievement of HbA1c 
lower than 58 mmol/mol was low among the two 
groups (66/143 (46%) CSII participants v 78/142 
(55%) MDI participants; relative risk 0.84 (95% 
confidence interval 0.67 to 1.06)). Incidence of severe 
hypoglycaemia and diabetic ketoacidosis were low 
in both groups. Fifty four non-serious and 14 serious 
adverse events were reported during CSII treatment, 
and 17 non-serious and eight serious adverse events 
during MDI treatment. Parents (but not children) 
reported superior PedsQL scores for those patients 
treated with CSII compared to those treated with MDI. 
CSII was more expensive than MDI by £1863 (€2179; 
$2474; 95% confidence interval £1620 to £2137) 
per patient, with no additional QALY gains (difference 
−0.006 (95% confidence interval −0.031 to 0.018)).
CONCLUSION
During the first year following type 1 diabetes 
diagnosis, no clinical benefit of CSII over MDI was 
identified in children and young people in the UK 
setting, and treatment with either regimen was 
suboptimal in achieving HbA1c thresholds. CSII was 
not cost effective.
TRIAL REGISTRATION
Current Controlled Trials ISRCTN29255275; European 
Clinical Trials Database 2010-023792-25.
WHAT IS ALREADY KNOWN ON THIS TOPIC
Intensive insulin regimens, multiple daily injections (MDI) and continuous 
subcutaneous insulin infusion (CSII), are associated with superior glycaemic 
control in patients with type 1 diabetes
Meta-analyses and economic evaluations reporting CSII to be a cost effective 
treatment are based on small randomised controlled trials and observational 
data, and are subject to considerable modelling
Results of a cluster randomised trial in adults with type 1 diabetes (REPOSE) did 
not support a policy of providing insulin pumps over multiple daily injections
WHAT THIS STUDY ADDS
In this randomised controlled trial and economic evaluation of infants, children, 
and young people in the first year of type 1 diabetes, glycaemic control was 
suboptimal in both treatment arms 
CSII treatment was not more clinically effective than treatment with MDI; 
furthermore, CSII as a standalone treatment was not cost effective
Parents of children treated with CSII, but not the children themselves, reported 
superior quality of life for their children compared with parents of children 
treated with MDI, below thresholds thought to be clinically significant
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Introduction
Type 1 diabetes is a common, chronic disease of 
childhood, affecting about 26 000 infants, children, 
and young people in the United Kingdom.1 Treatment 
requires administration of subcutaneous insulin 
in doses calculated according to carbohydrate 
consumption, physical activity, and blood glucose 
measurements. During childhood and adolescence, 
poor glycaemic control is associated with impaired 
memory,2 poorer cognitive outcomes,3 an increased 
risk of depression,4 and poor growth.5 In the longer 
term, vascular complications lead to blindness, 
renal failure, premature heart disease, stroke, and 
amputation.6 The risk of developing complications is 
related to glycaemic control, and is lower in patients 
treated with intensive regimens on insulin treatment: 
multiple daily injections (MDI) and continuous 
subcutaneous insulin infusion (CSII).7 There is no cure 
for type 1 diabetes, so optimal treatment is essential to 
enable the best possible quality of life and the effective 
use of healthcare resources while minimising the risk 
of complications.
A meta-analysis of six randomised controlled trials 
involving 165 children reported a modest benefit of 
CSII treatment on glycaemic control (as measured 
by glycated haemoglobin (HbA1c); −0.24%, 95% 
confidence interval −0.41% to −0.07%)8 albeit below 
the threshold associated with better clinical outcomes 
(0.5%),7 but no difference in the risk of severe 
hypoglycaemia or diabetic ketoacidosis.8 However, key 
limitations need to be considered when interpreting 
these results. 
Firstly, in five of the included randomised controlled 
trials, the observation period was insufficient (seven 
months or less) for the effects of treatment fatigue to 
be observed, and might not have been long enough 
for patients to become fully competent in the use of 
CSII. Secondly, isophane insulin use in the MDI arm of 
five included studies limits the generalisability of the 
results to modern regimens using longacting insulin 
analogues. Thirdly, in five of the six trials, patients 
with established type 1 diabetes treated with MDI 
were randomised to continue MDI treatment or change 
to CSII, which introduced selection bias. Patients in 
whom MDI treatment is satisfactory are less likely to be 
invited or to consent to participate than those patients 
in whom treatment is inadequate. In a more recent 
study, patients with established type 1 diabetes in 
whom MDI treatment was inadequate were randomised 
to either continue MDI treatment for six months or 
change to CSII; beneficial effects of CSII on quality of 
life were reported, but no effect on HbA1c was seen.9 
In a small randomised trial comparing CSII with MDI 
in patients newly diagnosed with type 1 diabetes and 
observed for two years, researchers saw no difference in 
glycaemic control or adverse events between treatment 
arms.10 Finally, at the start of CSII treatment, there is 
a period of intense education and frequent contact 
with diabetes healthcare professionals, which could 
favourably affect glycaemic control independently 
of CSII treatment in those patients with established 
diabetes. In the REPOSE study, when adults with 
type 1 diabetes and poor glycaemic control were 
randomised to treatment with CSII or MDI and given 
equivalent education, no additional benefit from CSII 
was identified.11
Observational studies of national paediatric 
databases from the United States, UK, Germany, and 
Austria have reported an association between CSII 
treatment and superior glycaemic control12 13 with 
only a modest effect. CSII use is lower in patients 
from ethnic minorities and those with greatest 
socioeconomic deprivation.14-16 Given that glycaemic 
control and severe hypoglycaemia are independently 
related to ethnicity and deprivation,14-16 there is a risk 
of bias, inherent to observational data, in estimates of 
the effect of CSII in these studies.
The cost of type 1 diabetes to the UK’s health service 
is significant, with estimates ranging from £1bn 
(€1.17bn; $1.33bn) to £1.8bn a year17 18 and expected 
to be nearly 2% of total NHS expenditure over the next 
two decades.17 A cost effectiveness analysis from the 
REPOSE study concluded that routine use of CSII in 
adults, without an immediate clinical need, would 
not be cost effective.19 The economic evidence, which 
indicates more expensive treatment with CSII to be cost 
effective in paediatrics,20 21 relies on data from limited 
trials and extensive modelling. Use of CSII in paediatric 
practice increased from 14% of patients in 2011 to 
28% in 2015-16.1 The widespread adoption of CSII, 
with little evidence of treatment superiority compared 
with MDI, requires an adequately powered randomised 
controlled trial, designed to address areas of bias 
inherent in previous studies. We therefore conducted 
the SCIPI trial (subcutaneous insulin: pumps or 
injections?), in which we recruited children and young 
people newly diagnosed with of type 1 diabetes and 
compared outcomes after one year of treatment.
Methods
Trial design
The study protocol has been previously published.22 
In brief, we conducted a pragmatic, multicentre, open 
label, parallel group, randomised controlled trial, 
randomising participants to CSII or MDI to compare 
the treatments’ efficacy, safety, and cost utility. The 
study was conducted in paediatric diabetes services 
experienced in the use of CSII, in nine university and 
six local hospitals within the NHS in England and 
Wales. The study opened to recruitment in May 2011 
and was closed in January 2017. The study protocol 
(supplementary appendix) was approved by the 
Liverpool East research ethics committee, reference 10/
H1002/80.
An internal pilot tested study feasibility, and 
the standard deviation used to inform the power 
calculation. A consent rate of at least 50%, with 
no differences likely to be of clinical significance 
in demographic criteria for age, ethnicity, sex, 
and deprivation score between those patients who 
consented and declined to participate was required to 
proceed to the full study. Study sites were selected on 
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the basis of the availability of a core set of experienced 
staff who had completed a recognised course on insulin 
pump therapy and had their competencies assessed 
and authorised.
Participants
Patients aged between 7 months and 15 years and 
with new diagnoses of type 1 diabetes were eligible to 
participate. Patients with the following characteristics 
were ineligible: previous treatment for type 1 diabetes, 
haemoglobinopathy, coexisting conditions or treatment 
likely to affect glycaemic control, psychological or 
psychiatric disorder, an allergy to a component of 
insulin aspart or determir (Novo Nordisk, Gatwick, UK) 
or insulin glargine (Sanofi, Guildford, UK), and a sibling 
with type 1 diabetes. Patients with thyroid disease 
or coeliac disease were eligible if thyroid hormone 
concentrations or coeliac antibodies demonstrated 
good adherence to treatment. Patients and carers 
were given written and age appropriate information 
about the study at diagnosis, supplemented by a video 
presented by participants and parents from February 
2014. Written informed consent or, where appropriate, 
assent was obtained from carers and participants.
Randomisation
Patients were randomised to treatment with CSII 
or MDI using 1:1, web based, block randomisation 
stratified by age (7 months to <5 years, 5 years to <12 
years, ≥12 years) and by treating centre. Participants 
were recruited by members of their local diabetes 
service and research nurses trained in the recruitment 
of paediatric patients. Parents and carers, and, when 
appropriate, patients, were invited to share reasons for 
declining to participate.
Procedures
We collected the following data at baseline, from the 
time of diagnosis of type 1 diabetes: blood pH, blood 
glucose, HbA1c, thyroid function tests, anti-islet cell 
and anti-glutamic acid decarboxylase antibodies, 
and tissue transglutaminase or other antibody test 
for coeliac disease measured per local practice before 
consent. These measurements were made prior to 
consent and did not form part of the study protocol. 
All participants completed a structured educational 
programme, which covered the syllabus outlined by 
the International Society for Paediatric and Adolescent 
Diabetes.23 This included the cause of type 1 diabetes, 
the use and administration of insulin, hyperglycaemia 
and correction doses of insulin, hypoglycaemia 
symptoms and treatment, exercise, sick day rules, 
carbohydrate counting, the benefits of maintaining 
optimal glycaemic control for long term health, and 
blood glucose monitoring. The number of education 
sessions was recorded to ensure parity across 
treatment arms. All participants received training on 
the use of MDI regimen and the Expert glucometer, with 
participants randomised to CSII receiving additional 
training in the use of CSII. All advanced pump features 
were taught, used, and regularly reviewed.
Randomised treatment started within 14 days of 
diagnosis of type 1 diabetes. Baseline height and 
weight were documented on the day randomised 
treatment began. Participants randomised to CSII were 
treated with insulin aspart, and those randomised 
to MDI with the shortacting insulin analogue insulin 
aspart and a longacting insulin analogue, either insulin 
glargine or detemir, according to local clinical practice. 
Insulin doses were calculated according to weight and 
age (see study protocol, web appendix 1), and titrated 
against blood glucose readings according to local 
protocols. Participants in both treatment arms used 
a glucometer that included a so-called bolus wizard, 
which calculated insulin doses according to blood 
glucose readings and carbohydrate consumption.
Study visits coincided with clinic appointments 
at three, six, nine, and 12 months. At each visit, the 
following data were collected: HbA1c, adverse events, 
height, weight, concomitant treatment and insulin 
use from prescriptions, glucometer and insulin pump 
downloads (CSII), and patient kept records (MDI). 
Participants and carers documented home episodes 
of severe hypoglycaemia24 and diabetic ketoacidosis 
in a diary. Treatment diaries and telephone logs were 
assessed at each study visit for any treatment related 
adverse events and related serious adverse events.25
In addition to self reporting, local hospital databases 
were interrogated at each clinical assessment to 
ascertain whether the participant had been treated for 
a related serious adverse event in the preceding three 
months. Adverse events were classified according 
to relation with the injection device, glucometer, 
insulin, errors in insulin administration, or incidental 
illness. The Health Utilities Index questionnaire26 was 
administered at baseline and each study visit, and the 
diabetes module of PedsQL (paediatric quality of life 
inventory)27 was completed at six and 12 months.
We measured resource use by using questionnaires 
and accessing prescription records and electronic, 
patient linked, information costing systems. These 
data included the purchase of pumps or MDI injection 
devices and associated consumables; purchase of 
insulins; contact with healthcare services including 
family doctors and school nurses; and hospital 
inpatient, outpatient, and emergency department 
attendances.
Data were collected on paper based case report 
forms and questionnaires, and entered centrally at 
the clinical trials unit into MACRO (InferMed, London, 
UK), a compliant clinical data management system. 
Bespoke software was developed to receive data 
downloaded from glucometers and pumps.
Outcome measures
The primary outcome measure was HbA1c 12 months 
following diagnosis of type 1 diabetes. Blood samples 
were analysed locally and centrally at Alder Hey 
Children’s Hospital, Liverpool, using the Siemens DCA 
Vantage HbA1c analyser. Within batch precision is 
less than 6% and between batch precision is less than 
8%. A limits of agreement analysis was undertaken for 
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measurements made in different laboratories and by 
“point of care” methods.28 Sensitivity analyses were 
performed using samples analysed centrally only, at 
point of care only, and central in preference to point of 
care if both were available. 
Secondary outcome measures were the percentage 
of patients in each treatment arm with HbA1c within 
the national target range29; incidence of severe 
hypoglycaemia (hypoglycaemia associated with 
altered consciousness) and diabetic ketoacidosis; 
change in standard deviation scores (SDS) of height 
and body mass index; insulin requirements (units/kg/
day); partial remission rate, defined as insulin dose 
adjusted HbA1c less than 9 (HbA1c (%) + (4×insulin 
dose (units/kg/day)))30; PedsQL score; and cost utility 
based on the incremental cost per quality adjusted life 
year (QALY) gained.
Statistical analysis
SCIPI was designed as a superiority trial assuming 
a null hypothesis of no difference. To detect a 
difference in HbA1c means of 0.5% (or 5.46 mmol/
mol conversion),31 the minimum difference generally 
considered to be clinically meaningful,7 with common 
standard deviation of 1.50 using a two group t test with 
a 0.05 two sided significance level, 286 participants 
(143 per group) were required to achieve 80% power. 
To allow for 10% loss to follow-up, the recruitment 
target was increased to 316 participants (158 per 
group).
The sample size calculation was based on HbA1c 12 
months following diagnosis.32 At the time of designing 
the trial, the association between HbA1c at diagnosis 
and longer term outcomes was speculative. Baseline 
HbA1c reflects blood glucose in the previous three 
months before insulin treatment. Two exploratory 
analyses were considered to include HbA1c measured 
at baseline as a continuous explanatory variable.
The intention-to-treat principle was used for the 
primary analysis such that all randomised participants 
in whom the outcome was observed were included in 
the group to which they were randomly allocated. We 
used a 0.05 level of statistical significance and 95% 
confidence intervals throughout. The statistical and 
health economic analysis plans33 were developed 
before analysis and are available as supplementary 
material. Analyses were conducted using SAS software 
(version 9.2; SAS Institute, Cary, NC, USA) or Stata 
(version 13; StataCorp, College Station, TX, USA). 
Independent statisticians from within the clinical trials 
unit produced and monitored the randomisation lists 
and statistical analysis plan,33 and undertook quality 
control via independent programming for the primary 
outcome and safety analyses. Blinding of the trial 
statistician was not possible, but inclusion of every 
participant within each analysis set was determined 
before use of allocation information.
For the primary outcome (HbA1c 12 months after 
randomisation), we used least squares regression 
adjusted for age category and centre as a random 
effect. Owing to the expected low incidence of 
events, secondary binary outcomes were presented 
as unadjusted relative risks. We undertook a per 
protocol analysis for the primary outcome to check 
the robustness of conclusions to major prespecified 
protocol deviations (table S2). Body mass index and 
height were standardised by use of WHO growth 
standards,34 35 and analysed by analysis of covariance 
including respective baseline measures, age group, 
and treatment group as covariates in the model with 
centre fitted as a random effect. Insulin requirements 
(units/kg/day) were calculated to reflect insulin use 
over a four week period, and then analysed as per 
growth outcomes without baseline measure to reflect 
the absence of insulin use in this untreated population 
before randomisation. PedsQL overall score (0-100) at 
12 months was calculated as per PedsQL guidelines 
according to the age specific questionnaires used, 
and then analysed as per growth outcomes. Partial 
remission rate at 12 months (defined as insulin dose 
adjusted HbA1c <9) was calculated using HbA1c, 
weight, and daily insulin dose, and then analysed as 
per binary outcomes. 
We conducted a safety analysis on adverse event data 
according to the method of insulin delivery at the time 
of the event. The incidence density rate was used to 
quantify the number of patients with at least one new 
case per population at risk in a given time period. The 
denominators were the sum of the person time in years 
for each treatment group (accounting for treatment 
switches) of the population at risk. For the cost utility 
analysis, we used UK Health Utilities Index Mark 2 
tariffs26 to estimate utilities and used the trapezoidal 
rule to calculate QALYs. Resource use was costed from 
the perspective of the NHS using the national tariff 
and other national unit costs. We compared the ratio 
of the differences between intervention groups in costs 
and QALYs with the NHS cost effectiveness threshold 
of £20 000 per QALY. The joint uncertainty in costs 
and QALYs was considered through 10 000 Bootstrap 
replicates (bias corrected and accelerated). A lifetime 
modelled extrapolation was only planned if differences 
in HbA1c were apparent between intervention groups 
at 12 months.
Patient and public involvement
Study design, delivery, and data interpretation were 
undertaken in close discussion with patients and their 
families. Young people were consulted on the design of 
the study including impact of participation, outcome 
measures, and study materials. Parents of children 
and young people with type 1 diabetes were members 
of the trial management committee and trial steering 
committee and advised on recruitment strategy. 
Study results and their significance to patients and 
their families were discussed in detail with parent 
contributors.
Results
Internal pilot
Recruitment data from the internal pilot study showed 
acceptable consent rates, showed no evidence of 
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patient selection bias, and supported the parameters 
used in the sample size calculation. The oversight 
committees recommended progression to the full 
study. Data from patients recruited to the internal pilot 
study were included in the full study.
Study participants
Between May 2011 and January 2016, 976 patients 
diagnosed as having type 1 diabetes were assessed 
for eligibility in 15 study centres. Of 689 patients who 
were eligible and approached for consent, 294 (43%, 
CSII=144, MDI=149) consented to participate. One 
patient withdrew before starting their randomised 
treatment. The sample size calculation was inflated 
to 316 participants to allow for 10% attrition, but 
the observed attrition was lower such that the trial 
was stopped after 294 randomisations to provide the 
numbers required to achieve 80% power (fig 1). Of 
patients invited to participate in SCIPI who declined 
to be randomised, 66% (259/395) stated that they (or 
their parent/carer) had a strong preference for MDI and 
10% (39/395) stated that they had a strong preference 
for CSII.
Of those randomised to CSII, 80% (91/114) of 
participants and 92% (130/142) of parents/carers 
received their favoured preferred treatment, compared 
with 37% (41/112) of participants and 28% (42/148) 
of parents/carers randomised to MDI (P<0.001). Age, 
sex, ethnicity, and deprivation score did not differ 
between those who consented to participate and those 
who declined (table S1), or between treatment arms 
(table 1).
Adherence to the protocol
A CONSORT diagram illustrating the pathway of 
patients from diagnosis to study completion is given in 
figure 1. Retention and adherence data are reported in 
figure S1 and table S2. All participants received their 
allocated interventions other than one participant who 
withdrew consent immediately after randomisation. Of 
144 participants initially assigned to CSII, 21 (15%) 
switched to MDI, and 30 (20%) of 149 participants 
switched from MDI to CSII. Primary outcome data were 
available for 97% (285/293) of participants. Primary 
and secondary outcome measures are provided in table 
2 and table 3.
Primary outcome
The treatment arms were comparable for HbA1c at 
12 months, with differences between the treatment 
Assessed for eligibility
Excluded
Eligibility criteria not met
Declined to participate
   MDI preference
   CSII preference
   Other
Other reasons
98
395
189
259
36
100
Allocated to MDI
Received MDI149Received CSII144
Allocated to CSII
976
Withdrew consent for
collected data to be used
682
Randomised
Analysed
Excluded from analysis
   Withdrew from trial prior to 12 months
1
1
143
Analysed
Excluded from analysis
   Withdrew from trial prior to 12 months
5
5
144
149144
Withdrew from trial
Relocated
Coeliac disease, unable to
  comply with gluten free diet
Personal circumstances
Lost to follow-up
Permanently changed insulin
  delivery method during trial
2
1
1
1
31
Withdrew from trial
No longer wished to participate
Permanently changed insulin
  delivery method during trial
1
22
1
1
5
294
Fig 1 | CONSORT diagram illustrating patient flow from diagnosis to completion of the study protocol. CSII=continuous 
subcutaneous insulin infusion; MDI=multiple daily injections
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arms being small and unimportant in the intention-
to-treat analysis (CSII, n=143, MDI, n=142; table 
2; table S3 shows full primary outcome results split 
by age group) and per protocol analysis. Sensitivity 
analyses demonstrated robustness of results to the 
measurement of HbA1c at central laboratory and point 
of care (table S4). Figure S2 shows details of HbA1c 
by age group and at each time point. The study was 
not powered to detect differences in glycaemic control 
between age groups. However, the observed HbA1c 
values were generally lower for the youngest and oldest 
age groups during MDI treatment, although there is 
a lot of uncertainty when comparing across groups. 
A forest plot showed the stability of treatment effect 
over time (figure S3), despite changes in NHS diabetes 
care during the SCIPI trial. Forest plots of the primary 
Table 1 | Baseline characteristics of study participants
Continuous subcutaneous 
insulin infusion (n=144)
Multiple daily injections 
(n=149)
Total  
(n=293)
Age at randomisation
Median (interquartile range) 9.9 (5.7-12.2) 9.4 (5.8-12.5) 9.8 (5.7-12.3)
Age group (No (%))
7 months to <5 years 33 (22.9) 32 (21.5) 65 (22.2)
5 to <12 years 71 (49.3) 76 (51) 147 (50.2)
12 to 15 years 40 (27.8 41 (27.5) 81 (27.6)
Sex (No (%))
Female 71 (49.3) 69 (46.3) 140 (47.8)
Male 73 (50.7) 80 (53.7) 153 (52.2)
Ethnicity (self reported)
Missing data (No) 1 3 4
Asian or Asian British (No (%)) 3 (2) 3 (2) 6 (2)
Black or British black (No (%)) 0 3 (2) 3 (1)
British white (No (%)) 124 (87) 118 (81) 242 (84)
Indian (No (%)) 2 (1) 2 (1) 4 (1)
Mixed (No (%)) 4 (3) 6 (4) 10 (4)
Other white (No (%)) 6 (4) 8 (6) 14 (5)
Other (No (%)) 3 (2) 2 (1) 5 (2)
Pakistani (No (%)) 1 (1) 4 (3) 5 (2)
Deprivation score*
Missing data (No) 7 6 13
Median (interquartile range) 19.4 (8.9-37.9) 14.7 (7.8-31.8) 17 (8.4-35.8)
Body mass index† SDS
Missing data (No) 20 17 37
Mean (standard deviation) 0.2 (1.3) 0.1 (1.4) 0.1 (1.3)
Height SDS
Missing data (No) 20 17 37
Mean (standard deviation) 0.3 (1.1) 0.3 (1.1) 0.3 (1.1)
HbA1c (mmol/mol)
Missing data (No) 12 18 30
Mean (standard deviation) 104.6 (24.4) 102.6 (26.7) 103.6 (25.5)
Blood glucose (mmol/L)
Missing data (No) 3 3 6
Mean (standard deviation) 26.8 (9.2) 26.9 (10) 26.9 (9.6)
Blood pH
Missing data (No) 17 16 33
Mean (standard deviation) 7.3 (0.2) 7.3 (0.1) 7.3 (0.2)
SDS=standard deviation score.
*Deprivation score ranges from 0 to 100, with 100 indicating greater deprivation.
†Body mass index=weight (kg) divided by the square of height (m).
Table 2 | Primary and secondary outcome measures (continuous)
Continuous outcomes
Total No of participants, adjusted mean (95% CI) Adjusted mean difference  
(95% CI) PCSII (n=144) MDI (n=149)
HbA1c (mmol/mol) at 12 months (primary outcome)
 Intention-to-treat analysis*† 143, 60.9 (58.5 to 63.3) 142, 58.5 (56.1 to 60.9) 2.4 (−0.4 to 5.3) 0.09
 Per protocol† 87, 60.2 (56.4 to 63.9) 66, 59.3 (55.3 to 63.2) 0.9 (−3.2 to 5.0) 0.67
Change in body mass index SDS*‡ 122, 0.6 (0.8) 122, 0.5 (0.8) 0.1 (0 to 0.3) 0.13
Change in height SDS*§ 122, −0.1 (0.5) 122, 0 (0.4) −0.1 (−0.2 to 0) 0.10
Insulin requirements (units/kg/day)*† 87, 0.7 (0.2) 64, 0.6 (0.3) 0.1 (0.0 to 0.2) 0.01
CSII=continuous subcutaneous insulin infusion; MDI=multiple daily injections; SDS=standard deviation score.
*Intention-to-treat analysis.
†Analysis adjusted for randomisation group (age category, fixed effects; centre, random effects).
‡Analysis adjusted for randomisation group (age category, fixed effects; centre, random effects) and body mass index standard deviation score at 
baseline.
§Analysis adjusted for randomisation group (age category, fixed effects; centre, random effects) and height standard deviation score at baseline.
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outcome split by subgroup (figure S4) also showed 
consistency of treatment effect across age groups and 
SCIPI centres.
The trial was powered to detect a difference in HbA1c 
between groups at 12 months unadjusted for baseline 
HbA1c values. The prognostic value of significance 
of HbA1c at diagnosis of type 1 diabetes was not well 
recognised at the time SCIPI opened to recruitment. 
Two exploratory analyses were considered to include 
HbA1c measured at baseline as a continuous 
explanatory variable (table S5). These results did not 
alter the SCIPI study conclusions for CSII compared 
with MDI at 12 months (adjusted mean difference 2.9 
mmol/mol, 95% confidence interval −0.02 to 5.9), but 
did suggest the importance of early baseline values 
for 12 month measurements (HbA1c level baseline 
coefficient estimate 0.07; standard error 0.03, 95% 
confidence interval 0.01 to 0.13).
A second exploratory analysis considered the 
effect of deprivation (table S7). Although we saw 
an association between higher HbA1c values at 
baseline and at 12 months with greater deprivation, 
the conclusions remained unaltered (adjusted mean 
differences in HbA1c at 12 months between treatment 
groups (CSII-MDI) were 2.9 mmol/mol (95% confidence 
interval −0.02 to 5.9) and 2.2 mmol/mol (−0.7 to 5.0), 
respectively).
Secondary outcomes
Secondary outcomes were analysed as per intention 
to treat (table 2 and table 3). We saw no difference in 
the number of participants achieving HbA1c targets 
(<58 mmol/mol, the national target until August 2015; 
and <48 mmol/mol, the target set in August 201528). 
Change in body mass index and height SDS were 
similar between treatment arms. 
Insulin dose data were available for 52% of 
participants (CSII, n=87/144, MDI, n=64/149). 
Insulin requirements were higher in those treated with 
CSII (adjusted mean difference 0.1 units/kg/day, 95% 
confidence interval 0.0 to 0.2, P=0.01), primarily in the 
oldest participants. The basal bolus ratio for patients 
treated with CSII, across the lifetime of the study, 
was 0.8. The ratio started from 0.73 at one month 
fluctuating up and down throughout the course of the 
trial, ending at 0.67 at 12 months (figure S5 and table 
S6). Similar data for MDI were not as robust because 
they depended on patient reporting.
Eight episodes of severe hypoglycaemia (CSII=6, 
MDI=2) and two episodes of diabetic ketoacidosis 
(CSII=2, MDI=0) were reported. Safety dataset reports 
events were categorised according to the treatment the 
participant received at the time of the adverse event, 
and took into account temporary or permanent switches 
in the method of insulin delivery. The total number of 
events experienced and the number of participants 
experiencing at least one event were provided, along 
with the incidence density rate (defined as the number 
of patients with at least one new adverse event per 
population at risk in a given time period).
Of 54 non-serious adverse events reported in 36 
participants treated with CSII at the time of the adverse 
event, 29 were related to the insulin pump, with an 
incidence density rate of 25.0 participants and at least 
one event per 100 person years. Of 17 non-serious 
adverse events reported in 16 participants (incidence 
density rate 10.5 participants) treated with MDI at 
the time of the adverse event, two were related to 
the injection device. Fourteen serious adverse events 
were reported in nine participants (incidence density 
rate 6.2 participants) treated with CSII at the time of 
the serious adverse event, and eight serious adverse 
events in eight participants (incidence density rate 5.3 
participants) treated with MDI at the time of the serious 
adverse event. Adverse event data are summarised in 
table 4. Patients randomised to CSII had twice as many 
related emergency department visits and inpatient 
stays related to type 1 diabetes (122 visits made by 
35/144 patients), compared with those randomised 
to MDI (60 visits made by 25/149 patients; mean 
difference 0.4 per patient, 95% confidence interval 
0.1 to 0.9). Reasons for those adverse events recorded 
as serious are provided in table 4.Child reported 
PedsQL scores (diabetes module) at 12 months were 
available for 71% of individuals (CSII, n=104; MDI, 
n=104), but 26 children in each treatment group 
were too young to complete the questionnaire. An 
adjusted mean difference at 12 months of 3.1 (95% 
confidence interval −0.6 to 6.8) favoured CSII, but 
the result was not statistically significant. Parents 
of participants (CSII, n=128/144, MDI, n=123/149) 
reported a statistically significantly higher score with 
CSII that with MDI (adjusted mean difference 4.1 (95% 
confidence interval 0.6 to 7.6)), but this result should 
be interpreted against meaningful differences being 
five points or more.36
Table 3 | Secondary outcome measures (binary)
Binary outcomes
Total No, No (%) of participants
Relative risk (95% CI) PCSII (n=144) MDI (n=149)
HbA1c <58 mmol/mol*† 143, 66 (46.2) 142, 78 (54.9) 0.84 (0.67 to 1.06) 0.16
HbA1c <48 mmol/mol*† 143, 22 (15.4) 142, 29 (20.4) 0.75 (0.46 to 1.25) 0.28
Incidence of severe hypoglycaemia* 144, 6 (4.2) 149, 2 (1.3) 3.1 (0.6 to 15.1) 0.17
Incidence of diabetic ketoacidosis* 144, 2 (1.4) 149, 0 5.2 (0.3 to 106.8) 0.24
Partial remission (IDAAC <9)* 86, 21 (24.4) 64, 21 (32.8) 0.74 (0.45 to 1.24) 0.28
CSII=continuous subcutaneous insulin infusion; MDI=multiple daily injections; IDAAC=insulin dose adjusted glycated haemoglobin (HbA1c).
*Intention-to-treat analysis.
†58 mmol/mol was the national target up to August 2015; 48 mmol/mol was the target set in August 2015.
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We found 4.3 (95% confidence interval 0.6 to 8.0) 
more contacts with healthcare professionals per 
participant treated with CSII (21.2) than MDI (16.9), 
using texts, emails, and phone calls. Mean total costs 
were higher by £1863 (95% confidence interval 
£1620 to £2137) for CSII than for MDI; with the most 
of this difference (£1177) from the additional cost of 
consumables and device (undiscounted annual cost 
of £600 for CSII versus £80 for MDI; table 5). We 
saw no significant difference in QALYs between CSII 
(0.910) and MDI (0.916; mean difference −0.006, 95% 
confidence interval −0.031 to 0.018). The probability 
of CSII being more expensive and less effective than 
MDI was 0.69, with no likelihood of CSII being cost 
effective at a threshold of £20 000 per QALY.
Discussion
Principal findings
In this randomised controlled trial of paediatric 
patients with a new diagnosis of type 1 diabetes, 
CSII treatment was neither more clinically effective 
nor more cost-effective than MDI, by the standards 
of the NHS. This non-superiority was consistent 
across centres and strengthens the lack of evidence to 
Table 4 | Information regarding serious adverse events and non-serious adverse events recorded during trial period
Category and 
description of adverse 
event
Non-serious adverse events Serious adverse events
CSII (144.1 total person 
years, n=144)
MDI (151.9 total person 
years, n=149)
CSII (144.1 total person 
years, n=144)
MDI (151.9 total person 
years, n=149)
No of events Patients (IDR) No of events Patients (IDR) No of events Patients (IDR) No of events Patients (IDR)
All
Diabetic ketoacidosis 2 2 (1.4) 0 0 (0) 2 2 (1.4) 0 0 (0)
Insulin administration error 2 2 (1.4) 5 5 (3.3) 2 2 (1.4) 3 3 (2)
Pump failure 4 3 (2.1) 0 0 (0) 0 0 (0) 0 0 (0)
Severe hypoglycaemia 6 6 (4.2) 2 2 (1.3) 1 1 (0.7) 0 0 (0)
Site infections 8 7 (4.9) 0 0 (0) 1 1 (0.7) 0 0 (0)
Other - to specify 32 22 (15.3) 10 10 (6.6) 8 6 (4.2) 5 5 (3.3)
Device
Diabetic ketoacidosis 1 1 (0.7) 0 0 (0) 1 1 (0.7) 0 0 (0)
Pump failure 4 3 (2.1) 0 0 (0) 0 0 (0) 0 0 (0)
Severe hypoglycaemia 2 2 (1.4) 0 0 (0) 0 0 (0) 0 0 (0)
Site infections 8 7 (4.9) 0 0 (0) 1 1 (0.7) 0 0 (0)
Other - to specify 14 11 (7.6) 3 3 (2) 0 0 (0) 0 0 (0)
Carer error
Insulin administration error 1 1 (0.7) 4 4 (2.6) 0 0 (0) 0 0 (0)
Other - to specify 5 2 (1.4) 0 0 (0) 1 1 (0.7) 0 0 (0)
Meter error
Other - to specify 3 3 (2.1) 1 1 (0.7) 5 4 (2.8) 2 2 (1.3)
Incidental illness
Insulin administration error 1 1 (0.7) 0 0 (0) 1 1 (0.7) 0 0 (0)
Other - to specify 5 5 (3.5) 3 3 (2) 0 0 (0) 1 1 (0.7)
Other
Diabetic ketoacidosis 1 1 (0.7) 0 0 (0) 1 1 (0.7) 0 0 (0)
Insulin administration error 0 0 (0) 1 1 (0.7) 3 2 (1.4) 3 3 (2)
Severe hypoglycaemia 4 4 (2.8) 2 2 (1.3) 1 1 (0.7) 2 2 (1.3)
Other - to specify 5 4 (2.8) 3 3 (2) 0 0 (0) 0 0 (0)
CSII=continuous subcutaneous insulin infusion; MDI=multiple daily injections; IDR=incidence density rate.
Table 5 | Resource use in participants treated with CSII versus MDI
Items of resource use
Cost (£; mean (95% CI))
CSII MDI Difference
Device (pump* with four year lifespan or two pen devices) 600 (596 to 606) 80 (80 to 80) 520 (516 to 526)
Consumables* (eg, needles, infusion sets, reservoirs) 1841 (1826 to 1861) 664 (664 to 664) 1177 (1162 to 1197)
Insulin (prescribed) 422 (364 to 486) 482 (426 to 541) −60 (−142 to 24)
Healthcare professional contacts (telephone calls, faxes, texts, or emails) 138 (117 to 162) 108 (92 to 124) 30 (3 to 59)
Scheduled outpatients visits 434 (434 to 434) 434 (434 to 434) 0 (0 to 0)
Unscheduled outpatient visits 309 (272 to 346) 328 (292 to 366) −19 (−71 to 33)
Inpatient stays costed from healthcare resource groups 387 (245 to 553) 219 (142 to 306) 168 (5 to 352)
Emergency department visits 26 (16 to 39) 13 (8 to 19) 13 (2 to 27)
Other hospital related items (eg, ward visits) 3 (1 to 7) 3 (1 to 5) 1 (−3 to5)
Family doctor visits 71 (56 to 88) 57 (45 to 69) 15 (−5 to 35)
Home visits 106 (80 to 138) 83 (66 to 100) 23 (−9 to 59)
School visits 53 (43 to 64) 56 (44 to 69) −3 (−19 to 13)
Concomitant treatments 12 (8 to 17) 15 (8 to 23) −2 (−12 to 6)
Total cost 4404 (4197 to 4642) 2541 (2412 to 2672) 1863 (1620 to 2137)
£1=€1.16; $1.32. CSII=continuous subcutaneous insulin infusion; MDI=multiple daily injections; 
*25% discount not included.
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support CSII. There is evidence that glycaemic control 
in the first year of diagnosis is predictive of longer term 
outcomes,37 38 and this is likely to be a critical period 
of care. Partial recovery of insulin production during 
the first year of diagnosis could substantially alter the 
treatment paradigm compared with the later stages in 
the course of type 1 diabetes, and our findings should 
not be applied beyond the first year of diagnosis.
Strengths and limitations of study
Our data are strengthened by a high retention rate 
and consistency of age, sex, ethnicity, and deprivation 
between treatment arms. Furthermore, age, sex, 
ethnicity, and deprivation did not differ between those 
patients who consented and those who declined to 
participate. Participants were recruited at diagnosis 
of type 1 diabetes, and core diabetes education and 
contact with healthcare professionals was balanced 
across treatment arms.
Our recruitment rate was lower than predicted 
and was strongly influenced by early treatment 
preference. The diagnosis of type 1 diabetes has been 
associated with symptoms of posttraumatic stress 
disorder in parents,39 and for some families it may 
not have been possible to contemplate randomisation 
to a new treatment so soon after diagnosis. Had we 
deferred recruitment, we might have achieved higher 
recruitment rates. At the point of randomisation, 
those patients randomised to treatment with CSII 
were significantly more likely to have received their 
preferred treatment and it is likely that we recruited 
a population of patients favouring CSII, which could 
explain the higher numbers of patients switching 
from MDI to CSII during follow-up. Examination of 
glycaemic control at the time of switching did not 
indicate poorer control. Future studies should examine 
how preference and disappointment might influence 
utilisation of randomised treatments.
The intention-to-treat analysis included all 
participants in the group that they were randomised to 
while the per protocol analysis excluded participants 
with major protocol deviations, which included 
switching method of insulin delivery. This difference 
allows some consideration of the effect, and although 
both analyses were not significant, the conclusions 
are robust. In addition, to account for participants 
who switched method of insulin delivery, the safety 
population analysed participants in the group to the 
method of insulin delivery at the time of the safety event.
The National Paediatric Diabetes Audit (NPDA) 
reports improvements in glycaemic control from 2010-
11 (72 mmol/mol in England and 70 mmol/mol in 
Wales) to 2016-17 (64 mmol/mol, both in England 
and Wales).1 During this period, several national 
initiatives have been undertaken that are likely to 
have contributed to this sustained improvement. 
However, only 15% of patients treated with CSII and 
20% of patients treated with MDI achieved an HbA1c 
within the target range at the end of the first year of 
treatment. Glycaemic control is poorer in the UK than 
other European and North America country, where 
CSII is used more commonly,11 leading to speculation 
that increased use of CSII could improve glycaemic 
control. The relative inexperience of NHS practitioners 
in CSII treatment could have obscured the potential 
benefits of this treatment. However, study sites were 
selected on the availability of a core set of trained and 
experienced staff. We saw no evidence of a treatment 
effect over time, and block randomisation ensured 
balance between treatment arms.
The development, validation, documentation, and 
monitoring of an education package and treatment 
protocols would have strengthened the study, but this 
would have incurred significant additional cost and 
delays, in the absence of robust evidence to inform 
the development of these protocols. Standardisation 
of educational packages is ideal, but it is important 
that these can be individualised to meet the needs of 
patients and their families. The pace at which education 
can be delivered to an unselected cohort of patients 
with newly diagnosed diabetes will be more measured 
than education of selected patients experienced in 
the treatment of type 1 diabetes, and it might be 
unrealistic to expect all families to achieve a high level 
of sophistication in CSII use. Additional education in 
CSII use could have reduced the prevalence of adverse 
events in this arm and improved glycaemic control, 
although this should be set in the context of the adult 
study, INPUT, which reported no effect of a structure 
education programme on glycaemic control in patients 
treated with CSII.40
Many adverse events were reported in the study 
cohort, which is consistent with the background 
population of patients with childhood type 1 diabetes 
treated with CSII. The NPDA reports that CSII treatment 
increased the risk of being admitted to hospital for 
diabetic ketoacidosis by 23%, and of being admitted 
to hospital for reasons other than diabetic ketoacidosis 
or hypoglycaemia by 27%. CSII treatment did not 
confer benefit or increased risk from admission with 
hypoglycaemia.41
The speed of technological developments outpaces 
the time required to deliver a clinical trial. It could be 
argued that the findings of the SCIPI trial are outdated: 
technology has advanced, clinical teams have greater 
experience of CSII, and improved education programmes 
and psychological support equips patients and their 
families to manage this treatmemt more successfully 
with fewer adverse events. However, observational 
data from the most mature CSII services report benefits 
in HbA1c below thresholds thought to be clinically 
meaningful,9 13 taking no account of the effect of 
deprivation or ethnicity on clinical outcomes. Enhanced 
education and psychological support also has the 
potential to improve quality of life and clinical outcomes 
in patients treated with MDI. To improve the timeframes 
required to deliver the evidence, development of a 
clinical trial platform should be considered.
Comparison with other studies
Our findings are consistent with those reported in a 
smaller randomised controlled trial of patients with 
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newly diagnosed type 1 diabetes,9 and previous studies 
of patients with the established disease.10 42-44 Authors 
of a systematic review of adult and paediatric patients 
concluded that CSII enabled superior glycaemic control 
and quality of life than MDI with fewer episodes of 
hypoglycaemia, but cautioned that the inclusion of 
observational data could have introduced bias.45
The reported effect of CSII on quality of life and 
treatment satisfaction varies.10 40-42 In our study, 
parents of participants treated with CSII reported a 
small, but significantly higher PedsQL score for the 
quality of life of their children. A qualitative approach 
could detect differences in quality of life that were not 
identified in our questionnaire based approach. No 
adjustments for multiplicity were applied to secondary 
outcomes, and SCIPI was not powered to detect 
differences within these outcomes. Consequently, the 
results should not be judged solely on the presence or 
absence of statistical significance.
Tools for recording insulin use were less robust in 
those treated with MDI than CSII, and difficulties with 
data downloads from glucometers and pumps, and 
missing data in handheld records resulted in a large 
amount of missing data. In contrast with previous 
studies,13 18 20 insulin requirements were higher in 
patients treated with CSII than MDI, which could reflect 
a reduction in the intensity of MDI treatment as older 
participants gain independence, or under-reporting. 
Recognising this uncertainty, our data relating to 
partial remission should be interpreted with caution.
Conclusions and policy implications
Many patient advocacy groups and healthcare 
professionals are of the strong opinion that treatment 
with CSII is beneficial and further research should 
focus on determining what these perceived benefits are 
and on developing validated tools to measure them. 
Individual patients are likely to experience benefits 
from this treatment that are not directly associated with 
the outcomes measured in this study. For example, 
preschool children who consume carbohydrates and 
exercise erratically could benefit from a treatment 
with fewer injections and a basal insulin profile that 
can be modified readily. For the SCIPI cohort, longer 
term observation is required to assess how treatment in 
the first year has influenced the trajectory of glycaemic 
control in future years.
Evolving technology that automates glucose 
monitoring and insulin dose adjustment has the 
potential to reduce the burden of CSII treatment on 
patients and families, and enable superior glycaemic 
control to that reported in SCIPI participants. These 
technologies are likely to be considerably more 
expensive than those evaluated in this study and 
evidence should be sought to support their use.
In considering the outcomes of the SCIPI study 
it is important to recognise three points. Firstly, 
glycaemic control was suboptimal in both treatment 
arms. Secondly, patients recruited to the study were 
newly diagnosed, and more favourable results could 
be achieved with CSII in patients more experienced in 
the treatment of type 1 diabetes. Thirdly, advances in 
technology could reduce the burden of CSII treatment, 
and facilitate superior control in time.
In resource limited settings, the introduction of 
novel, expensive treatment should be informed by 
robust clinical data demonstrating superiority. Data 
from the SCIPI study indicate that the use of CSII was 
neither clinically beneficial nor cost effective in the 
first year of type 1 diabetes, and resources could be 
more effectively invested in other measures to improve 
glycaemic control.
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